This poor prognosis is partly due to the immunosuppressive tumor microenvironment, which includes tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and immune checkpoint molecules such as PD-1/PD-L1, all contributing to immune evasion and resistance to therapies (6–8). This evidence concerns the gene CD274 and neoplasm.